Shares in AIM-listed infection prevention specialist Tristel (LON:TSTL) climbed by 3.68% to 492.50p (as of 12:00 BST) after the firm announced its Duo range of disinfectants have been approved for use on certain medical devices in India.
CEO Paul Swiney commented: “Every regulatory approval we achieve represents an important milestone in our progress, and this Indian approval for the use of our high-level disinfectants on invasive medical devices is no exception. The three Duo products provide Indian hospitals with an affordable and easy-to-use high-level disinfection method for medical devices used in ultrasound, ophthalmology, and gynaecology. Infection prevention experts within India acknowledge the need for disinfection technologies that will enable hospitals to raise their decontamination standards. Combining these latest approvals with those previously gained gives us a broad product offering for the Indian market.
“We can now press on with developing our commercial plan for India. We have initiated discussions with various potential partners for distribution of the products“.